Svetlana Lucas boasts nearly two decades of experience in working with top-tier biotech companies in both small and big settings. She has proven her expertise in strategy, business development, commercialization, and new product planning. After studying at Moscow State University and Caltech, Svetlana built a skill set in business and strategy with top management consulting firm, McKinsey & Company. She now serves as the Chief Business Officer at Scribe Therapeutics; however, she has held various roles, including Board Member at aTyr Pharma, SVP of Business Development at Tizona Therapeutics Inc., and Executive Director and Head of Oncology and Inflammation external R&D at Amgen. Throughout her career, Svetlana has showcased her professional prowess, which has helped her excel in her roles and earn her highly respected reputation in the biotech industry.